Acute Respiratory Distress Syndrome Clinical Trial Pipeline Shows Potential with Active Contributions from 40+ Key Companies | DelveInsight

The ARSD clinical trial analysis report delivers important insights into ongoing research of 45+ pipeline ARSD drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

New York, USA, April 09, 2026 (GLOBE NEWSWIRE) -- Acute Respiratory Distress Syndrome Clinical Trial Pipeline Shows Potential with Active Contributions from 40+ Key Companies | DelveInsight

The ARSD clinical trial analysis report delivers important insights into ongoing research of 45+ pipeline ARSD drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

DelveInsight’s 'Acute Respiratory Distress Syndrome Pipeline Insight 2026' report provides comprehensive global coverage of pipeline therapies for acute respiratory distress syndrome across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the acute respiratory distress syndrome domain.

Acute Respiratory Distress Syndrome Clinical Trial Analysis Summary

DelveInsight’s acute respiratory distress syndrome pipeline report depicts a robust space with 40+ active players working to develop 45+ pipeline acute respiratory distress syndrome drugs.
Key acute respiratory distress syndrome companies such as Staidson (Beijing) Biopharmaceuticals Co., Ltd, GEn1E Lifesciences, Aqualung Therapeutics Corp., Dompé Farmaceutici S.p.A., Vasomune Therapeutics, Implicit Bioscience, Edesa Biotech, MiNK Therapeutics, BioAegis Therapeutics, Direct Biologics, AVM Biotechnology, Athersys, EXORPHIA, EnliTISA (Shanghai) Pharmaceutical, LEAF4Life, Savara Pharmaceuticals, Tiziana Life Sciences, Factor Bioscience, LTT Bio Pharma, Orbsen Therapeutics, and others are evaluating new acute respiratory distress syndrome drugs to improve the treatment landscape.
Promising pipeline acute respiratory distress syndrome therapies, such as STSA 1002, GEn 1124, ALT-100, Reparixin, AV-001, Atibuclimab, EB05, AGENT 797, Rhu-pGSN, ExoFlo, AVM0703, Invimestrocel, EXP01, TISA-818, LEAF-4L6715, Molgramostim, TZLS-501, NC-MSC, LT1001, Orbcel C, and others, are in different phases of ARSD clinical trials.
Approximately 20+ ARSD drugs are in the mid stage of development, whereas 22+ drugs are in the early stages of development.

Notable MoAs in acute respiratory distress syndrome clinical trials include Complement C5a inhibitor Mitogen-activated protein kinase 14 inhibitor, Nicotinamide phosphoribosyltransferase inhibitor, CXCR1/ CXCR2 Inhibitor, TIE-2 receptor agonists, CD14 antigen inhibitor, and others.

Request a sample and discover the recent advances in ARSD drugs @ Acute Respiratory Distress Syndrome Pipeline Report

What is Acute Respiratory Distress Syndrome?

Acute Respiratory Distress Syndrome (ARDS) is a rapidly advancing condition seen in critically ill patients. Its primary complication involves the leakage of fluid into the lungs, severely impairing or preventing normal breathing and leading to dangerously low blood oxygen levels. ARDS typically develops in individuals who are already suffering from another serious illness or major trauma, resulting in fluid accumulation within the alveoli and disruption of pulmonary surfactant. The causes of ARDS are broadly classified into direct and indirect lung injuries. Direct causes include conditions such as pneumonia, aspiration, and physical trauma to the lungs. Indirect causes arise from systemic insults, including pancreatitis, severe infections (sepsis), blood transfusions, extensive burns, and adverse drug reactions.

Find out more about acute respiratory distress syndrome drugs @ Acute Respiratory Distress Syndrome Treatment

A snapshot of the Pipeline Acute Respiratory Distress Syndrome Drugs mentioned in the report:

Drugs	Company	Phase	MoA	RoA
STSA 1002	Staidson (Beijing) Biopharmaceuticals Co., Ltd	III	Complement C5a inhibitor	Intravenous
GEn 1124	GEn1E Lifesciences	II	Mitogen-activated protein kinase 14 inhibitor	Intravenous
ALT-100	Aqualung Therapeutics Corp.	II	Nicotinamide phosphoribosyltransferase inhibitor	Intravenous
Reparixin	Dompe Farmaceutici	II	CXCR1/ CXCR2 Inhibitor	Oral
AV-001	Vasomune Therapeutics	II	TIE-2 receptor agonists	Intravenous bolus
Atibuclimab	Implicit Bioscience	II	CD14 antigen inhibitor	Intravenous

Learn more about the emerging ARSD therapies @ Acute Respiratory Distress Syndrome Clinical Trials

Stuti Mahajan, consulting manager at DelveInsight, said that ARDS remains a high-burden critical care condition with significant unmet need, driven by its complex pathophysiology and lack of targeted pharmacological therapies. Despite advances in supportive care, mortality remains high, highlighting limited treatment impact. Emerging approaches such as anti-inflammatory and cell-based therapies show promise, but clinical heterogeneity continues to challenge development.

Recent Developments in Acute Respiratory Distress Syndrome Treatment Space

In February 2026, Edesa Biotech announced positive additional data from a Phase III study of paridiprubart. Par Nijhawan, MD, Chief Executive Officer of Edesa Biotech, stated that the results announced support the central role of TLR4 in hyperinflammatory ARDS and demonstrate a consistent benefit across high-mortality etiologies. The drug is currently being evaluated in a separate US government-funded study of ARDS patients.
In October 2025, Edesa Biotech, a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics (HDTs) for immuno-inflammatory diseases, announced positive results from a Phase III study evaluating the company’s drug candidate paridiprubart (EB05) as a treatment for Acute Respiratory Distress Syndrome. The data from the Phase III study demonstrated that paridiprubart met primary and secondary endpoints with statistical significance.
In June 2025, BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to its lead product candidate, recombinant human plasma gelsolin (rhu-pGSN) for the treatment of acute respiratory distress syndrome.
In June 2025, NuvOx Therapeutics announced that the first patient has been dosed for its EXTEND trials: novEl oXygen ThErapeutic NanO2 for mild respiratory distress in Phase Ib and ARDS in Phase II Trials.
In May 2024, Vasomune Therapeutics announced that the FDA has granted Fast Track designation to AV-001, an investigational drug in development to prevent or treat moderate-to-severe acute respiratory distress syndrome (ARDS) in patients with respiratory infections. According to the company, Phase I data demonstrated the safety and pharmacokinetic profile of AV-001, backing once-daily dosing. Additionally, the treatment showed support for strong Tie2 activation. AV-001 is currently recruiting patients for a Phase IIa trial as an ARDS treatment in pneumonia.
In November 2023, Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases associated with vascular dysfunction, announced that their lead drug candidate AV-001 has received a positive recommendation from the Independent Data and Safety Monitoring Board (IDSMB) of the AV001-004 Phase IIa Study. The Phase IIa trial (NCT05123755) evaluated the efficacy, safety, and tolerability of AV-001 in patients suffering with Acute Respiratory Distress Syndrome.

Scope of the Acute Respiratory Distress Syndrome Pipeline Report

Coverage: Global
Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
Therapeutics Assessment By Mechanism of Action: Complement C5a inhibitor Mitogen-activated protein kinase 14 inhibitor, Nicotinamide phosphoribosyltransferase inhibitor, CXCR1/ CXCR2 Inhibitor, TIE-2 receptor agonists, CD14 antigen inhibitor, and others.
Key Acute Respiratory Distress Syndrome Companies:Staidson (Beijing) Biopharmaceuticals Co., Ltd, GEn1E Lifesciences, Aqualung Therapeutics Corp., Dompé Farmaceutici S.p.A., Vasomune Therapeutics, Implicit Bioscience, Edesa Biotech, MiNK Therapeutics, BioAegis Therapeutics, Direct Biologics, AVM Biotechnology, Athersys, EXORPHIA, EnliTISA (Shanghai) Pharmaceutical, LEAF4Life, Savara Pharmaceuticals, Tiziana Life Sciences, Factor Bioscience, LTT Bio Pharma, Orbsen Therapeutics, and others.
Key Acute Respiratory Distress Syndrome Pipeline Therapies: STSA 1002, GEn 1124, ALT-100, Reparixin, AV-001, Atibuclimab, EB05, AGENT 797, Rhu-pGSN, ExoFlo, AVM0703, Invimestrocel, EXP01, TISA-818, LEAF-4L6715, Molgramostim, TZLS-501, NC-MSC, LT1001, Orbcel C, and others.

Dive deep into rich insights for new acute respiratory distress syndrome treatments, visit @ Acute Respiratory Distress Syndrome Drugs

Table of Contents

1.	Acute Respiratory Distress Syndrome Pipeline Report Introduction
2.	Acute Respiratory Distress Syndrome Pipeline Report Executive Summary
3.	Acute Respiratory Distress Syndrome Pipeline: Overview
4.	Analytical Perspective In-depth Commercial Assessment
5.	Acute Respiratory Distress Syndrome Clinical Trial Therapeutics
6.	Acute Respiratory Distress Syndrome Pipeline: Late-Stage Products (Pre-registration)
7.	Acute Respiratory Distress Syndrome Pipeline: Late-Stage Products (Phase III)
8.	Acute Respiratory Distress Syndrome Pipeline: Mid-Stage Products (Phase II)
9.	Acute Respiratory Distress Syndrome Pipeline: Early-Stage Products (Phase I)
10.	Acute Respiratory Distress Syndrome Pipeline Therapeutics Assessment
11.	Inactive Products in the Acute Respiratory Distress Syndrome Pipeline
12.	Company-University Collaborations (Licensing/Partnering) Analysis
13.	Key Companies
14.	Key Products in the Acute Respiratory Distress Syndrome Pipeline
15.	Unmet Needs
16.	Market Drivers and Barriers
17.	Future Perspectives and Conclusion
18.	Analyst Views
19.	Appendix

For further information on the acute respiratory distress syndrome cure research, reach out @ Medication for Acute Respiratory Distress Syndrome Treatment

Acute Respiratory Distress Syndrome Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted ARDS epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Acute Respiratory Distress Syndrome Market

Acute Respiratory Distress Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ARDS companies, including MediciNova, Edesa Biotech, Light Chain Biosciences, Mesoblast Limited, Veru, APEPTICO Forschung und Entwicklung GmbH, Pluristem Therapeutics, Avalo Therapeutics, Boehringer Ingelheim, Genentech, Windtree Therapeutics, Biomarck Pharmaceuticals, Athersys, Healios, Direct Biologics, Biohaven Pharmaceutical, Arch Biopartners, ILTOO Pharma, Cartesian Therapeutics, AVEM HealthCare, Vitti Labs, LLC, GEn1E Lifesciences, MiNK Therapeutics, Longeveron Inc., Reven Pharmaceuticals, Inc., Dompé Farmaceutici S.p.A, Vasomune Therapeutics, Inc., Aerogen Pharma Limited, among others.

Chronic Obstructive Pulmonary Disease Market

Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key chronic obstructive pulmonary disease companies, including Sanofi, Chiesi Farmaceutici S.p.A., United Therapeutics Corporation, Verona Pharma plc, Immunotek, Yungjin Pharm. Co., Ltd., Pulmotect, Inc., Tetherex Pharmaceutical, CSL Behring, AstraZeneca, Novartis, Genentech, Vertex Pharmaceuticals, EmeraMed, Afimmune, Mereo BioPharma, Synairgen, Adamis Pharmaceuticals, Quercegen Pharmaceuticals LLC, Regend Therapeutics, Meridigen Biotech Co., Ltd., Pulmatrix, Eisai, GlaxoSmithKline, EpiEndo Pharmaceuticals, 3SBio, OmniSpirant, Foresee Pharmaceuticals, Amgen, Organicell Regenerative Medicine, Arrowhead Pharmaceuticals, ProterixBio, RS BioTherapeutics, MitoRx, C4X Discovery, Respiratorius, ARK biosciences, Incannex, GNI Pharma, Celon pharma, Alveolus Bio, Kinaset therapeutics, Landos Biopharma, Parion Sciences, KeyMed Biosciences, Bioneer corporation, AlgiPharma, Palobiofarma, Dimerix Bioscience, Glenmark Pharmaceuticals, among others.

Chronic Obstructive Pulmonary Disease Clinical Trial Analysis

Chronic Obstructive Pulmonary Disease Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key COPD companies, including Sanofi, Chiesi Farmaceutici S.p.A., United Therapeutics Corporation, Verona Pharma plc, Immunotek, Yungjin Pharm. Co., Ltd., Pulmotect, Inc., Tetherex Pharmaceutical, CSL Behring, AstraZeneca, Novartis, Genentech, Vertex Pharmaceuticals, EmeraMed, Afimmune, Mereo BioPharma, Synairgen, Adamis Pharmaceuticals, Quercegen Pharmaceuticals LLC, Regend Therapeutics, Meridigen Biotech Co., Ltd., Pulmatrix, Eisai, GlaxoSmithKline, EpiEndo Pharmaceuticals, 3SBio, OmniSpirant, Foresee Pharmaceuticals, Amgen, Organicell Regenerative Medicine, Arrowhead Pharmaceuticals, ProterixBio, RS BioTherapeutics, MitoRx, C4X Discovery, Respiratorius, ARK biosciences, Incannex, GNI Pharma, Celon pharma, Alveolus Bio, Kinaset therapeutics, Landos Biopharma, Parion Sciences, KeyMed Biosciences, Bioneer corporation, AlgiPharma, Palobiofarma, Dimerix Bioscience, Glenmark Pharmaceuticals, among others.

Asthma Market

Asthma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key asthma companies including GlaxoSmithKline, 4D Pharma plc, AstraZeneca, Suzhou Connect Biopharmaceuticals, Avillion, Pearl Therapeutics, ARS Pharmaceuticals, Sinomab, Avalo Therapeutics, Kymab, Sanofi, Cumberland Pharmaceuticals, Genentech, Inc., among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.

Contact Us

Shruti Thakur 

info@delveinsight.com 

+14699457679

www.delveinsight.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.